Warfarin-5-FU interaction - A consecutive case series

被引:47
作者
Kolesar, JM
Johnson, CL
Freeberg, BL
Berlin, JD
Schiller, JH
机构
[1] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA
[2] Univ Wisconsin, Sch Med, Madison, WI USA
[3] William S Middleton Mem Vet Adm Med Ctr, Nursing Serv, Madison, WI 53705 USA
[4] Univ Cincinnati, Adjunct Ambulatory Care Fac, Cincinnati, OH USA
[5] Vanderbilt Univ, Med Ctr, Div Hematol Oncol, Nashville, TN USA
来源
PHARMACOTHERAPY | 1999年 / 19卷 / 12期
关键词
D O I
10.1592/phco.19.18.1445.30897
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Five patients from a single institution received concomitant warfarin and 5-fluorouracil (5-FU) during a 3-year period. The mean weekly warfarin dose before starting chemotherapy was 40.66 mg and during chemotherapy it was 24 mg (p=0.0026). All patients required a warfarin dosage reduction (range 18-74%, mean 44%). Two patients were hospitalized, one with a major retroperitoneal bleed, the other for fresh-frozen plasma administration and observation. Maximum international normalized ratios (INRs) ranged from 3.66-23.7. This series confirms a common, clinically significant interaction between warfarin and 5-FU. An interaction between capecitabine, the orally available prodrug of S-FU, and warfarin also has been reported. We recommend weekly monitoring of prothrombin time and INR for all patients receiving concomitant warfarin and 5-FU or capecitabine.
引用
收藏
页码:1445 / 1449
页数:5
相关论文
共 18 条
[1]   Modulation of the expression of constitutive rat hepatic cytochrome P450 isozymes by 5-fluorouracil [J].
Afsar, A ;
Lee, C ;
Riddick, DS .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1996, 74 (02) :150-156
[2]  
BENEDETTI F, 1999, IMPORTANT PRESCRIBIN
[3]   Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer [J].
Blum, JL ;
Jones, SE ;
Buzdar, AU ;
LoRusso, PM ;
Kuter, I ;
Vogel, C ;
Osterwalder, B ;
Burger, HU ;
Brown, CS ;
Griffin, T .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :485-493
[4]  
BOOTH BW, 1981, NEW ENGL J MED, V305, P170
[5]  
Brown MC, 1997, PHARMACOTHERAPY, V17, P631
[6]   RELIANCE ON PROTHROMBIN TIME RATIOS CAUSES SIGNIFICANT ERRORS IN ANTICOAGULATION THERAPY [J].
BUSSEY, HI ;
FORCE, RW ;
BIANCO, TM ;
LEONARD, AD .
ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (02) :278-282
[7]  
CHLEBOWSKI RT, 1982, CANCER RES, V42, P4827
[8]   Hemostasis and malignancy [J].
Francis, JL ;
Biggerstaff, J ;
Amirkhosravi, A .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1998, 24 (02) :93-109
[9]   Mechanism of action, clinical effectiveness, and optimal therapeutic range [J].
Hirsh, J ;
Dalen, JE ;
Anderson, DR ;
Poller, L ;
Bussey, H ;
Ansell, J ;
Deykin, D ;
Brandt, JT .
CHEST, 1998, 114 (05) :445S-469S
[10]   Human P450 metabolism of warfarin [J].
Kaminsky, LS ;
Zhang, ZY .
PHARMACOLOGY & THERAPEUTICS, 1997, 73 (01) :67-74